# | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
---|---|---|---|---|---|---|---|---|---|
1. | ALA4836706 | F | Antiinflammatory activity BALB/c mouse assessed as inhibition of carbachol-induced bronchial reactivity at 10 mg/kg, po administered on day 0 and 7 and measured upto 21 days | Mus musculus | 1 | ALA4834471 | organism-based format | Scientific Literature | |
2. | ALA4836707 | F | Antiinflammatory activity against ovalbumin-induced airway hyperreactivity in BALB/c mouse assessed as reduction in LTB4 and isomers level in lung tissue at 10 mg/kg, po pretreated with compound for 60 mins prior to ovalbumin stimulation on day 0 and 7 and measured upto 21 days by UPLC-MS/MS analysis | Mus musculus | 1 | ALA4834471 | organism-based format | Scientific Literature | |
3. | ALA4836708 | A | Drug concentration in plasma of mouse at 10 mg/kg, po within 1 hr | Mus musculus | 1 | ALA4834471 | organism-based format | Scientific Literature | |
4. | ALA4836709 | A | Drug degradation in mouse at 10 mg/kg, po | Mus musculus | 1 | ALA4834471 | organism-based format | Scientific Literature | |
5. | ALA4836710 | F | Induction of CYP3A4 expression in human HepaRG cells at 0.1 to 10 uM incubated for 48 hrs by fluorescence based assay | Homo sapiens | 1 | ALA4834471 | cell-based format | Scientific Literature | |
6. | ALA4836711 | A | Drug metabolism in human liver-on-chip assessed as compound conjugation with sulfate incubated for 48 hrs by UPLC-MS/MS analysis | Homo sapiens | 1 | ALA4834471 | tissue-based format | Scientific Literature | |
7. | ALA4836712 | A | Drug metabolism in human liver-on-chip assessed as compound oxidization at 12a' or 13' of omega-carboxylic acid incubated for 48 hrs by UPLC-MS/MS anlaysis | Homo sapiens | 1 | ALA4834471 | tissue-based format | Scientific Literature | |
8. | ALA4836713 | B | Inhibition of recombinant human 5-LOX expressed in Escherichia coli BL21 (DE3) cells preincubated for 10 mins followed by arachidonic acid addition and measured after 10 mins by RP-HPLC method | Homo sapiens | 47 | ALA4834471 | cell-based format | Scientific Literature | |
9. | ALA4836714 | B | Inhibition of recombinant human 5-LOX expressed in Escherichia coli BL21 (DE3) cells assessed as residual activity at 1 uM preincubated for 10 mins followed by arachidonic acid addition and measured after 10 mins by RP-HPLC method relative to control | Homo sapiens | 47 | ALA4834471 | cell-based format | Scientific Literature | |
10. | ALA4836715 | B | Inhibition of 5-LOX in human PMNL assessed as reduction in 5-LOX product formation preincubated for 10 mins before addition of AA and A23187 and measured after 10 mins by RP-HPLC method | Homo sapiens | 47 | ALA4834471 | tissue-based format | Scientific Literature | |
11. | ALA4836716 | B | Inhibition of 5-LOX in human PMNL assessed as residual activity by measuring reduction in 5-LOX product formation at 3 uM preincubated for 10 mins before addition of AA and A23187 and measured after 10 mins by RP-HPLC method relative to control | Homo sapiens | 47 | ALA4834471 | tissue-based format | Scientific Literature | |
12. | ALA4836717 | B | Inhibition of recombinant human 5-LOX expressed in Escherichia coli BL21 (DE3) cells at 0.03 to 1 uM using varying concentrations of arachidonic acid as substrate preincubated for 15 mins followed by substrate addition and measured after 5 mins | Homo sapiens | 1 | ALA4834471 | cell-based format | Scientific Literature | |
13. | ALA4836718 | B | Reversible inhibition of recombinant human 5-LOX at 0.3 uM using varying concentrations of arachidonic acid as substrate preincubated for 15 mins followed by substrate addition and measured after 5 mins | Homo sapiens | 1 | ALA4834471 | single protein format | Scientific Literature | |
14. | ALA4836719 | B | Inhibition of recombinant human 5-LOX at 0.03 to 0.3 uM using arachidonic acid as substrate preincubated for 15 mins followed by substrate addition and measured after 5 mins in presence of Triton X-100 | Homo sapiens | 1 | ALA4834471 | single protein format | Scientific Literature | |
15. | ALA4836720 | F | Antioxidant activity assessed as DPPH radical scavenging activity at 0.1 to 10 uM incubated for 30 mins by microplate reader based assay | 1 | ALA4834471 | assay format | Scientific Literature | ||
16. | ALA4836721 | B | Inhibition of human 5-LOX Trp102Ala/Trp13Ala/Trp75Ala triple mutant expressed in Escherichia coli BL21 (DE3) cells at 0.03 to 1 uM preincubated for 10 mins followed by arachidonic acid addition and measured after 10 mins by RP-HPLC method | Homo sapiens | 1 | ALA4834471 | cell-based format | Scientific Literature | |
17. | ALA4836722 | B | Inhibition of human 5-LOX Arg101Asp mutant expressed in Escherichia coli BL21 (DE3) cells at 0.03 to 1 uM preincubated for 10 mins followed by arachidonic acid addition and measured after 10 mins by RP-HPLC method | Homo sapiens | 1 | ALA4834471 | cell-based format | Scientific Literature | |
18. | ALA4836723 | B | Inhibition of 5-LOX in human PMNL assessed as reduction in 5-LOX product formation preincubated for 10 mins before addition of A23187 and measured after 10 mins | Homo sapiens | 1 | ALA4834471 | tissue-based format | Scientific Literature | |
19. | ALA4836724 | B | Inhibition of 5-LOX in human PMNL assessed as intracellular accumulation of compound at 150 nM after 20 mins by UPLC-MS/MS analysis | Homo sapiens | 1 | ALA4834471 | tissue-based format | Scientific Literature | |
20. | ALA4836725 | B | Inhibition of 5-LOX in LPS-stimulated human monocytes assessed as reduction in 5-LOX product formation prestimulated with LPS for 24 hrs followed by compound addition for 15 mins followed by AA and A23187 addition by UPLC-MS.MS analysis | Homo sapiens | 2 | ALA4834471 | cell-based format | Scientific Literature |